Peter Higgins, MD
Interventional Cardiology · Lewiston, MENPI 1700866142
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Boston Scientific at 36.8% of the total. Reporting peaked in 2023 at $1,301 and has fallen 87.8% since, to $158 in 2025.
Across 38 payments — averaging $98.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Edwards Lifesciences$965
- Abbott$756
- Teleflex LLC$216
- Abiomed$147
- Shockwave Medical, Inc$93
- plus $201 from 5 others
What the payments were for
- Travel & lodging$2,07155%
- Food & beverage$1,69045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $1,383 |
| Edwards Lifesciences | 9 | $965 |
| Abbott | 6 | $756 |
| Teleflex LLC | 2 | $216 |
| Abiomed | 2 | $147 |
| Shockwave Medical, Inc | 1 | $93 |
| Biotronik Inc. | 2 | $82 |
| Medtronic(2 entities) | 3 | $68 |
| Penumbra, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,761 in reported general payments places this provider in the 65th percentile of 21 interventional cardiology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 20 | $35,299 |
| EliquisApixaban | 27 | $34,473 |
| FarxigaDapagliflozin Propanediol | 28 | $32,103 |
| Repatha SureclickEvolocumab | 33 | $30,188 |
| Praluent PenAlirocumab | 16 | $9,411 |
| Metoprolol Succinate | 65 | $857 |
| Rosuvastatin Calcium | 20 | $805 |
| Ezetimibe | 31 | $528 |
| Atorvastatin Calcium | 29 | $462 |
| Losartan Potassium | 41 | $335 |
| Furosemide | 41 | $265 |
| Spironolactone | 35 | $258 |
| Carvedilol | 25 | $191 |
| Amlodipine Besylate | 32 | $168 |
| ClopidogrelClopidogrel Bisulfate | 15 | $138 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Lewiston
- Arun ThukkaniLewiston$8K
- Bryce EinhornLewiston$5K
- Andrew EisenhauerLewiston$2K
- Michael BerlowitzLewiston$631
- Szymon WiernekScarborough$22K
- Srikanth RadhakrishnanBangor$7K
- Ellie MuellerAugusta$6K
- Jay ShahScarborough$5K
- Matthew McKayBangor$4K
- Thomas EarlBangor$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.